Regeneron Pharmaceuticals, Inc. v. Amgen Inc.

Regeneron Rips Amgen's 'Bundling Scheme' Amid IP Feud

Regeneron Pharmaceuticals Inc. has launched a new antitrust lawsuit accusing Amgen of an illegal "bundling scheme" aimed at destroying the market for Regeneron's cholesterol medication Praluent and boosting sales of its main rival product, Amgen's Repatha.